Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study
G Rostoker, M Griuncelli, C Loridon, R Couprie… - The American journal of …, 2012 - Elsevier
BACKGROUND: Most dialysis patients receiving erythropoesis-stimulating agents (ESA)
also receive parenteral iron supplementation. There are few data on the risk of
hemosiderosis in this setting. METHODS: We prospectively measured liver iron
concentration by means of T1 and T2* contrast magnetic resonance imaging (MRI) without
gadolinium, in a cohort of 119 fit hemodialysis patients receiving both parenteral iron and
ESA, in keeping with current guidelines. RESULTS: Mild to severe hepatic iron overload was …
also receive parenteral iron supplementation. There are few data on the risk of
hemosiderosis in this setting. METHODS: We prospectively measured liver iron
concentration by means of T1 and T2* contrast magnetic resonance imaging (MRI) without
gadolinium, in a cohort of 119 fit hemodialysis patients receiving both parenteral iron and
ESA, in keeping with current guidelines. RESULTS: Mild to severe hepatic iron overload was …
